CellCentric secures funding to take its prostate cancer programme to IND.October 20th 2015:Further investment from Morningside Venture Investments Ltd and Providence Investment Company Ltd will see the company take its small molecule drug discovery programme for the most aggressive form of prostate cancer (CRPC) through candidate finalisation and IND-enabling studies. CellCentric’s proprietary compounds target a histone acetyl transferase (HAT) that is key in androgen receptor regulation.
CellCentric successfully completes InnovateUK programme.October 15th 2015:CellCentric is developing small molecule inhibitors for the most aggressive form of prostate cancer (CRPC). In March 2013, the company secured support from InnovateUK, combined with venture capital investment, to develop novel small molecule modulators of the androgen receptor pathway. This programme has now completed, on time and on budget.